BAY2927088
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for BAY2927088, covering 2024-06-20 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) [Phase 1, Phase 2]